Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods.

ABSTRACT: Monoclonal antibodies are biopharmaceuticals with a very long half-life due to the binding of their Fc portion to the neonatal receptor (FcRn), a pharmacokinetic property that can be further improved through engineering of the Fc portion, as demonstrated by the approval of several new drugs. Many Fc variants with increased binding to FcRn have been found using different methods, such as structure-guided design, random mutagenesis, or a combination of both, and are described in the literature as well as in patents. Our hypothesis is that this material could be subjected to a machine learning approach in order to generate new variants with similar properties. We therefore compiled 1323 Fc variants affecting the affinity for FcRn, which were disclosed in twenty patents. These data were used t

SUBMITTER: Dumet C 

PROVIDER: S-EPMC10052518 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature